Drug intelligence / Profile preview

cigarette reduced nicotine

Development stage
Phase 3
Lead developer
22nd Century Group
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Inhalation
01

Overview

Reduced nicotine cigarettes are manufactured tobacco cigarettes in which the nicotine content has been intentionally lowered to minimally addictive or nonaddictive levels. These products are designed to reduce the potential for addiction and dependence by delivering much less nicotine than conventional cigarettes. Mechanistically, they provide a similar sensory and behavioral experience as regular cigarettes but with significantly less pharmacologically active nicotine delivered to the user. Clinical studies have shown that switching to reduced-nicotine cigarettes can decrease overall smoking behavior, reduce exposure to tobacco toxicants (such as NNAL), lower dependence on nicotine, and promote abstinence from smoking[3][4][6]. The primary public health rationale is that reducing the addictiveness of commercial tobacco products may help people smoke less or quit entirely[4][7]. Reduced-nicotine standards for cigarettes are under consideration by regulatory agencies such as the FDA.

Brand names
VLN KingVLN Menthol King
Other names
very low nicotine content cigarettereduced nicotine content cigaretteVLNC cigaretteRNC cigarette
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on cigarette reduced nicotine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cigarette reduced nicotine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call